BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28699788)

  • 21. Cryopreservation and Revival of Human Mesenchymal Stromal Cells.
    Haack-Sørensen M; Ekblond A; Kastrup J
    Methods Mol Biol; 2016; 1416():357-74. PubMed ID: 27236683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Production of good manufacturing practice-grade human umbilical cord blood-derived mesenchymal stem cells for therapeutic use.
    Van Pham P; Phan NK
    Methods Mol Biol; 2015; 1283():73-85. PubMed ID: 25239529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges.
    Jossen V; van den Bos C; Eibl R; Eibl D
    Appl Microbiol Biotechnol; 2018 May; 102(9):3981-3994. PubMed ID: 29564526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Production of oncolytic adenovirus and human mesenchymal stem cells in a single-use, Vertical-Wheel bioreactor system: Impact of bioreactor design on performance of microcarrier-based cell culture processes.
    Sousa MF; Silva MM; Giroux D; Hashimura Y; Wesselschmidt R; Lee B; Roldão A; Carrondo MJ; Alves PM; Serra M
    Biotechnol Prog; 2015; 31(6):1600-12. PubMed ID: 26289142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate.
    Haack-Sørensen M; Juhl M; Follin B; Harary Søndergaard R; Kirchhoff M; Kastrup J; Ekblond A
    Scand J Clin Lab Invest; 2018 Jul; 78(4):293-300. PubMed ID: 29661028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy.
    Zhang J; Huang X; Wang H; Liu X; Zhang T; Wang Y; Hu D
    Stem Cell Res Ther; 2015 Dec; 6():234. PubMed ID: 26620426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Manufacture of Clinical-Grade Human Clonal Mesenchymal Stem Cell Products from Single Colony Forming Unit-Derived Colonies Based on the Subfractionation Culturing Method.
    Yi T; Kim SN; Lee HJ; Kim J; Cho YK; Shin DH; Tak SJ; Moon SH; Kang JE; Ji IM; Lim HJ; Lee DS; Jeon MS; Song SU
    Tissue Eng Part C Methods; 2015 Dec; 21(12):1251-62. PubMed ID: 26421757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies.
    Dwarshuis NJ; Parratt K; Santiago-Miranda A; Roy K
    Adv Drug Deliv Rev; 2017 May; 114():222-239. PubMed ID: 28625827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
    Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
    Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells.
    Eiro N; Fraile M; Schneider J; Vizoso FJ
    Curr Stem Cell Res Ther; 2018; 13(6):423-431. PubMed ID: 29701160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
    Golpanian S; DiFede DL; Pujol MV; Lowery MH; Levis-Dusseau S; Goldstein BJ; Schulman IH; Longsomboon B; Wolf A; Khan A; Heldman AW; Goldschmidt-Clermont PJ; Hare JM
    Oncotarget; 2016 Mar; 7(11):11899-912. PubMed ID: 26933813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives.
    Roh KH; Nerem RM; Roy K
    Annu Rev Chem Biomol Eng; 2016 Jun; 7():455-78. PubMed ID: 27276552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review.
    Vonk LA; de Windt TS; Slaper-Cortenbach IC; Saris DB
    Stem Cell Res Ther; 2015 May; 6(1):94. PubMed ID: 25976213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesenchymal stem cell therapy in treatment of erectile dysfunction: autologous or allogeneic cell sources?
    Mangir N; Akbal C; Tarcan T; Simsek F; Turkeri L
    Int J Urol; 2014 Dec; 21(12):1280-5. PubMed ID: 25074479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GMP scale-up and banking of pluripotent stem cells for cellular therapy applications.
    Ausubel LJ; Lopez PM; Couture LA
    Methods Mol Biol; 2011; 767():147-59. PubMed ID: 21822873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical grade expansion of MSCs.
    Capelli C; Pedrini O; Valgardsdottir R; Da Roit F; Golay J; Introna M
    Immunol Lett; 2015 Dec; 168(2):222-7. PubMed ID: 26092523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product.
    Wang M; Senger RS; Paredes C; Banik GG; Lin A; Papoutsakis ET
    Biotechnol Bioeng; 2009 Nov; 104(4):796-808. PubMed ID: 19591186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).
    Singh A; Singh A; Sen D
    Stem Cell Res Ther; 2016 Jun; 7(1):82. PubMed ID: 27259550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure.
    Westerdahl DE; Chang DH; Hamilton MA; Nakamura M; Henry TD
    Expert Opin Biol Ther; 2016 Sep; 16(9):1163-9. PubMed ID: 27376188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application.
    Torre ML; Lucarelli E; Guidi S; Ferrari M; Alessandri G; De Girolamo L; Pessina A; Ferrero I;
    Stem Cells Dev; 2015 Mar; 24(6):677-85. PubMed ID: 25517941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.